Neuropeptide Y: A stressful review

Neuropeptides

Volumn 55, Issue , 2016, Pages 99-109

  Reichmann, Florian ^a   Holzer, Peter ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Anxiety; Neurodegenerative diseases; Neuropeptide Y; Post traumatic stress disorder; Stress; Stress resilience; Stress induced feeding changes; Y1; Y2; Y5

Indexed keywords

NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR;

ANIMAL; HOMEOSTASIS; HUMAN; HYPOTHALAMUS; METABOLISM; NERVE CELL; PHYSIOLOGICAL STRESS; PHYSIOLOGY;

ANIMALS; HOMEOSTASIS; HUMANS; HYPOTHALAMUS; NEURONS; NEUROPEPTIDE Y; RECEPTORS, NEUROPEPTIDE Y; STRESS, PHYSIOLOGICAL;

EID: 84957839481     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2015.09.008     Document Type: Review

References (180)

1. Adam T.C., Epel E.S. Stress, eating and the reward system. Physiol. Behav. 2007, 91(4):449-458. (Jul 24).
2. Albuquerque M.S., Mahar I., Davoli M.A., Chabot J.G., Mechawar N., Quirion R., et al. Regional and sub-regional differences in hippocampal GABAergic neuronal vulnerability in the TgCRND8 mouse model of Alzheimer's disease. Front. Aging Neurosci. 2015, 7:30. (Mar 24).
3. Alexander S.P., Benson H.E., Faccenda E., Pawson A.J., Sharman J.L., Spedding M., et al. The concise guide to Pharmacology 2013/14: G protein-coupled receptors. Br. J. Pharmacol. 2013, 170(8):1459-1581. (Dec).
4. Allen Y.S., Adrian T.E., Allen J.M., Tatemoto K., Crow T.J., Bloom S.R., et al. Neuropeptide Y distribution in the rat brain. Science 1983, 221(4613):877-879. (Aug 26).
5. Amstadter A.B., Koenen K.C., Ruggiero K.J., Acierno R., Galea S., Kilpatrick D.G., et al. NPY moderates the relation between hurricane exposure and generalized anxiety disorder in an epidemiologic sample of hurricane-exposed adults. Depress. Anxiety 2010, 27(3):270-275. (Mar).
6. Angelucci F., Gelfo F., Fiore M., Croce N., Mathe A.A., Bernardini S., et al. The effect of neuropeptide Y on cell survival and neurotrophin expression in in-vitro models of Alzheimer's disease. Can. J. Physiol. Pharmacol. 2014, 92(8):621-630. (Aug).
7. Asakawa A., Inui A., Ueno N., Fujimiya M., Fujino M.A., Kasuga M. Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice. Peptides 1999, 20(12):1445-1448. (Dec).
8. Aydin C., Oztan O., Isgor C. Effects of a selective Y2R antagonist, JNJ-31020028, on nicotine abstinence-related social anxiety-like behavior, neuropeptide Y and corticotropin releasing factor mRNA levels in the novelty-seeking phenotype. Behav. Brain Res. 2011, 222(2):332-341. (Sep 23).
9. Aydin C., Oztan O., Isgor C. Hippocampal Y2 receptor-mediated mossy fiber plasticity is implicated in nicotine abstinence-related social anxiety-like behavior in an outbred rat model of the novelty-seeking phenotype. Pharmacol. Biochem. Behav. 2014, 125:48-54. (Oct).
10. Bacchi F., Mathe A.A., Jimenez P., Stasi L., Arban R., Gerrard P., et al. Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze. Peptides 2006, 27(12):3202-3207. (Dec).
11. Baker D.G., Bertram T.M., Patel P.M., Barkauskas D.A., Clopton P., Patel S., et al. Characterization of cerebrospinal fluid (CSF) and plasma NPY levels in normal volunteers over a 24-timeframe. Psychoneuroendocrinology 2013, 38(10):2378-2382. (Oct).
12. Bakshi V.P., Kalin N.H. Corticotropin-releasing hormone and animal models of anxiety: gene-environment interactions. Biol. Psychiatry 2000, 48(12):1175-1198. (Dec 15).
13. Bannon A.W., Seda J., Carmouche M., Francis J.M., Norman M.H., Karbon B., et al. Behavioral characterization of neuropeptide Y knockout mice. Brain Res. 2000, 868(1):79-87. (Jun 16).
14. Bardi M., Rhone A.P., Franssen C.L., Hampton J.E., Shea E.A., Hyer M.M., et al. Behavioral training and predisposed coping strategies interact to influence resilience in male Long-Evans rats: implications for depression. Stress 2012, 15(3):306-317. (May).
15. Baticic L., Detel D., Kucic N., Buljevic S., Pugel E.P., Varljen J. Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice. J. Cell. Biochem. 2011, 112(11):3322-3333. (Nov).
16. Beal M.F., Martin J.B. Neuropeptides in neurological disease. Ann. Neurol. 1986, 20(5):547-565. (Nov).
17. Benedek D.M. Posttraumatic stress disorder from Vietnam to today: the evolution of understanding during Eugene Brody's tenure at the Journal of Nervous and Mental Disease. J. Nerv. Ment. Dis. 2011, 199(8):544-552. (Aug).
18. Bercik P., Verdu E.F., Foster J.A., Lu J., Scharringa A., Kean I., et al. Role of gut-brain axis in persistent abnormal feeding behavior in mice following eradication of Helicobacter pylori infection. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296(3):R587-R594. (Mar).
19. Bernardi J.R., Ferreira C.F., Senter G., Krolow R., de Aguiar B.W., Portella A.K., et al. Early life stress interacts with the diet deficiency of omega-fatty acids during the life course increasing the metabolic vulnerability in adult rats. PLoS One 2013, 8(4). (Apr 17).
20. Bertocchi I., Oberto A., Longo A., Mele P., Sabetta M., Bartolomucci A., et al. Regulatory functions of limbic Y1 receptors in body weight and anxiety uncovered by conditional knockout and maternal care. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(48):19395-19400. (Nov 29).
21. Broberger C., Visser T.J., Kuhar M.J., Hokfelt T. Neuropeptide Y innervation and neuropeptide-Y-Y1-receptor-expressing neurons in the paraventricular hypothalamic nucleus of the mouse. Neuroendocrinology 1999, 70(5):295-305. (Nov).
22. Bromee T., Sjodin P., Fredriksson R., Boswell T., Larsson T.A., Salaneck E., et al. Neuropeptide Y-family receptors Y6 and Y7 in chicken. Cloning, pharmacological characterization, tissue distribution and conserved synteny with human chromosome region. FEBS J. 2006, 273(9):2048-2063. (May).
23. Caberlotto L., Fuxe K., Hurd Y.L. Characterization of NPY mRNA-expressing cells in the human brain: co-localization with Y2 but not Y1 mRNA in the cerebral cortex, hippocampus, amygdala, and striatum. J. Chem. Neuroanat. 2000, 20(3-4):327-337. (Dec).
24. Calvez J., Fromentin G., Nadkarni N., Darcel N., Even P., Tome D., et al. Inhibition of food intake induced by acute stress in rats is due to satiation effects. Physiol. Behav. 2011, 104(5):675-683. (Oct 24).
25. Cannizzaro C., Tel B.C., Rose S., Zeng B.Y., Jenner P. Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease. Brain Res. Mol. Brain Res. 2003, 110(2):169-176. (Feb 20).
26. Carvajal C.C., Vercauteren F., Dumont Y., Michalkiewicz M., Quirion R. Aged neuropeptide Y transgenic rats are resistant to acute stress but maintain spatial and non-spatial learning. Behav. Brain Res. 2004, 153(2):471-480. (Aug 31).
27. Chan-Palay V., Lang W., Allen Y.S., Haesler U., Polak J.M. Cortical neurons immunoreactive with antisera against neuropeptide Y are altered in Alzheimer's-type dementia. J. Comp. Neurol. 1985, 238(4):390-400. (Aug 22).
28. Chapman C.D., Frey W.H.,.2nd, Craft S., Danielyan L., Hallschmid M., Schioth H.B. Intranasal treatment of central nervous system dysfunction in humans. Pharm. Res. 2013, 30(10):2475-2484. (Oct).
29. Chigr F., Rachidi F., Tardivel C., Najimi M., Moyse E. Modulation of orexigenic and anorexigenic peptides gene expression in the rat DVC and hypothalamus by acute immobilization stress. Front. Cell. Neurosci. 2014, 8:198. (Jul 18).
30. Chrousos G.P. Stress and disorders of the stress system. Nat. Rev. Endocrinol. 2009, 5(7):374-381. (Jul).
31. Cippitelli A., Rezvani A.H., Robinson J.E., Eisenberg L., Levin E.D., Bonaventure P., et al. The novel, selective, brain-penetrant neuropeptide Y Y2 receptor antagonist, JNJ-31020028, tested in animal models of alcohol consumption, relapse, and anxiety. Alcohol 2011, 45(6):567-576. (Sep).
32. Cohen H., Kozlovsky N., Matar M.A., Zohar J., Kaplan Z. The characteristic long-term upregulation of hippocampal NF-kappaB complex in PTSD-like behavioral stress response is normalized by high-dose corticosterone and pyrrolidine dithiocarbamate administered immediately after exposure. Neuropsychopharmacology 2011, 36(11):2286-2302. (Oct).
33. Cohen H., Liu T., Kozlovsky N., Kaplan Z., Zohar J., Mathe A.A. The neuropeptide Y (NPY)-ergic system is associated with behavioral resilience to stress exposure in an animal model of post-traumatic stress disorder. Neuropsychopharmacology 2012, 37(2):350-363. (Jan).
34. Cohen S., Vainer E., Matar M.A., Kozlovsky N., Kaplan Z., Zohar J., et al. Diurnal fluctuations in HPA and neuropeptide Y-ergic systems underlie differences in vulnerability to traumatic stress responses at different zeitgeber times. Neuropsychopharmacology 2015, 40(3):774-790. (Feb).
35. Conrad C.D., McEwen B.S. Acute stress increases neuropeptide Y mRNA within the arcuate nucleus and hilus of the dentate gyrus. Brain Res. Mol. Brain Res. 2000, 79(1-2):102-109. (Jun 23).
36. Croce N., Ciotti M.T., Gelfo F., Cortelli S., Federici G., Caltagirone C., et al. Neuropeptide Y protects rat cortical neurons against beta-amyloid toxicity and re-establishes synthesis and release of nerve growth factor. ACS Chem. Neurosci. 2012, 3(4):312-318. (Apr 18).
37. Croce N., Dinallo V., Ricci V., Federici G., Caltagirone C., Bernardini S., et al. Neuroprotective effect of neuropeptide Y against beta-amyloid 25-35 toxicity in SH-SY5Y neuroblastoma cells is associated with increased neurotrophin production. Neurodegener. Dis. 2011, 8(5):300-309.
38. Croce N., Gelfo F., Ciotti M.T., Federici G., Caltagirone C., Bernardini S., et al. NPY modulates miR-30a-5p and BDNF in opposite direction in an in vitro model of Alzheimer disease: a possible role in neuroprotection?. Mol. Cell. Biochem. 2013, 376(1-2):189-195. (Apr).
39. Curtis M.A., Faull R.L., Eriksson P.S. The effect of neurodegenerative diseases on the subventricular zone. Nat. Rev. Neurosci. 2007, 8(9):712-723. (Sep).
40. Curtis M.A., Penney E.B., Pearson A.G., van Roon-Mom W.M., Butterworth N.J., Dragunow M., et al. Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(15):9023-9027. (Jul 22).
41. Dallman M.F., Akana S.F., Strack A.M., Hanson E.S., Sebastian R.J. The neural network that regulates energy balance is responsive to glucocorticoids and insulin and also regulates HPA axis responsivity at a site proximal to CRF neurons. Ann. N. Y. Acad. Sci. 1995, 771:730-742. (Dec 29).
42. Dawbarn D., De Quidt M.E., Emson P.C. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res. 1985, 340(2):251-260. (Aug 12).
43. de Lange R.P., Wiegant V.M., Stam R. Altered neuropeptide Y and neurokinin messenger RNA expression and receptor binding in stress-sensitised rats. Brain Res. 2008, 1212:35-47. (May 30).
44. Decressac M., Barker R.A. Neuropeptide Y and its role in CNS disease and repair. Exp. Neurol. 2012, 238(2):265-272. (Dec).
45. Decressac M., Pain S., Chabeauti P.Y., Frangeul L., Thiriet N., Herzog H., et al. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease. Neurobiol. Aging 2012, 33(9):2125-2137. (Sep).
46. Decressac M., Wright B., Tyers P., Gaillard A., Barker R.A. Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease. Exp. Neurol. 2010, 226(1):24-32. (Nov).
47. DiMaggio D.A., Chronwall B.M., Buchanan K., O'Donohue T.L. Pancreatic polypeptide immunoreactivity in rat brain is actually neuropeptide Y. Neuroscience 1985, 15(4):1149-1157. (Aug).
48. Djamshidian A., Lees A.J. Can stress trigger Parkinson's disease?. J. Neurol. Neurosurg. Psychiatry 2014, 85(8):878-881. (Aug).
49. Domschke K., Dannlowski U., Hohoff C., Ohrmann P., Bauer J., Kugel H., et al. Neuropeptide Y (NPY) gene: impact on emotional processing and treatment response in anxious depression. Eur. Neuropsychopharmacol. 2010, 20(5):301-309. (May).
50. Domschke K., Hohoff C., Jacob C., Maier W., Fritze J., Bandelow B., et al. Chromosome 4q31-34 panic disorder risk locus: association of neuropeptide Y Y5 receptor variants. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B(4):510-516. (Jun 5).
51. Donner J., Sipila T., Ripatti S., Kananen L., Chen X., Kendler K.S., et al. Support for involvement of glutamate decarboxylase 1 and neuropeptide Y in anxiety susceptibility. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2012, 159B(3):316-327. (Apr).
52. dos Santos V.V., Santos D.B., Lach G., Rodrigues A.L., Farina M., De Lima T.C., et al. Neuropeptide Y (NPY) prevents depressive-like behavior, spatial memory deficits and oxidative stress following amyloid-beta (Abeta(1-40)) administration in mice. Behav. Brain Res. 2013, 244:107-115. (May 1).
53. Dumont Y., Jacques D., Bouchard P., Quirion R. Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains. J. Comp. Neurol. 1998, 402(3):372-384. (Dec 21).
54. Eaton K., Sallee F.R., Sah R. Relevance of neuropeptide Y (NPY) in psychiatry. Curr. Top. Med. Chem. 2007, 7(17):1645-1659.
55. Escamilla-Sevilla F., Perez-Navarro M.J., Munoz-Pasadas M., Saez-Zea C., Jouma-Katati M., Piedrola-Maroto G., et al. Change of the melanocortin system caused by bilateral subthalamic nucleus stimulation in Parkinson's disease. Acta Neurol. Scand. 2011, 124(4):275-281. (Oct).
56. Eva C., Serra M., Mele P., Panzica G., Oberto A. Physiology and gene regulation of the brain NPY Y1 receptor. Front. Neuroendocrinol. 2006, 27(3):308-339. (Sep).
57. Farzi A., Reichmann F., Holzer P. The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour. Acta Physiol. (Oxf.) 2015, 213(3):603-627. (Mar).
58. Fendt M., Burki H., Imobersteg S., Lingenhohl K., McAllister K.H., Orain D., et al. Fear-reducing effects of intra-amygdala neuropeptide Y infusion in animal models of conditioned fear: an NPY Y1 receptor independent effect. Psychopharmacology 2009, 206(2):291-301. (Oct).
59. Ferenczi S., Zelei E., Pinter B., Szoke Z., Kovacs K.J. Differential regulation of hypothalamic neuropeptide Y hnRNA and mRNA during psychological stress and insulin-induced hypoglycemia. Mol. Cell. Endocrinol. 2010, 321(2):138-145. (Jun 10).
60. Forbes S., Herzog H., Cox H.M. A role for neuropeptide Y in the gender-specific gastrointestinal, corticosterone and feeding responses to stress. Br. J. Pharmacol. 2012, 166(8):2307-2316. (Aug).
61. Gehlert D.R. Role of hypothalamic neuropeptide Y in feeding and obesity. Neuropeptides 1999, 33(5):329-338. (Oct).
62. Gehlert D.R., Schober D.A., Gackenheimer S.L., Beavers L., Gadski R., Lundell I., et al. [125I]Leu31, Pro34-PYY is a high affinity radioligand for rat PP1/Y4 and Y1 receptors: evidence for heterogeneity in pancreatic polypeptide receptors. Peptides 1997, 18(3):397-401.
63. Goebel-Stengel M., Stengel A., Wang L., Tache Y. Orexigenic response to tail pinch: role of brain NPY(1) and corticotropin releasing factor receptors. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2014, 306(3):R164-R174. (Feb 1).
64. Hadad-Ophir O., Albrecht A., Stork O., Richter-Levin G. Amygdala activation and GABAergic gene expression in hippocampal sub-regions at the interplay of stress and spatial learning. Front. Behav. Neurosci. 2014, 8:3. (Jan 21).
65. Hallschmid M., Benedict C., Born J., Fehm H.L., Kern W. Manipulating central nervous mechanisms of food intake and body weight regulation by intranasal administration of neuropeptides in man. Physiol. Behav. 2004, 83(1):55-64. (Oct 30).
66. Hassan A.M., Jain P., Reichmann F., Mayerhofer R., Farzi A., Schuligoi R., et al. Repeated predictable stress causes resilience against colitis-induced behavioral changes in mice. Front. Behav. Neurosci. 2014, 8:386. (Nov 6).
67. Hawley D.F., Bardi M., Everette A.M., Higgins T.J., Tu K.M., Kinsley C.H., et al. Neurobiological constituents of active, passive, and variable coping strategies in rats: integration of regional brain neuropeptide Y levels and cardiovascular responses. Stress 2010, 13(2):172-183. (Mar).
68. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 2004, 38(4):213-224. (Aug).
69. Heilig M., Koob G.F., Ekman R., Britton K.T. Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci. 1994, 17(2):80-85. (Feb).
70. Heilig M., Soderpalm B., Engel J.A., Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology 1989, 98(4):524-529.
71. Herman J.P., Cullinan W.E. Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci. 1997, 20(2):78-84. (Feb).
72. Hoffman J.R., Ostfeld I., Kaplan Z., Zohar J., Cohen H. Exercise enhances the behavioral responses to acute stress in an animal model of PTSD. Med. Sci. Sports Exerc. 2015, (Feb 19).
73. Holzer P., Reichmann F., Farzi A. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides 2012, 46(6):261-274. (Dec).
74. Ito K., Bahry M.A., Hui Y., Furuse M., Chowdhury V.S. Acute heat stress up-regulates neuropeptide Y precursor mRNA expression and alters brain and plasma concentrations of free amino acids in chicks. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 2015, 187:13-19. (Sep).
75. Ito M., Dumont Y., Quirion R. Mood and memory-associated behaviors in neuropeptide Y5 knockout mice. Neuropeptides 2013, 47(2):75-84. (Apr).
76. Johnson D.C., Thom N.J., Stanley E.A., Haase L., Simmons A.N., Shih P.A., et al. Modifying resilience mechanisms in at-risk individuals: a controlled study of mindfulness training in Marines preparing for deployment. Am. J. Psychiatry 2014, 171(8):844-853. (Aug).
77. Kallupi M., Vendruscolo L.F., Carmichael C.Y., George O., Koob G.F., Gilpin N.W. Neuropeptide YY(2)R blockade in the central amygdala reduces anxiety-like behavior but not alcohol drinking in alcohol-dependent rats. Addict. Biol. 2014, 19(5):755-757. (Sep).
78. Karl T., Burne T.H., Herzog H. Effect of Y1 receptor deficiency on motor activity, exploration, and anxiety. Behav. Brain Res. 2006, 167(1):87-93. (Feb 15).
79. Kas M.J., Bruijnzeel A.W., Haanstra J.R., Wiegant V.M., Adan R.A. Differential regulation of agouti-related protein and neuropeptide Y in hypothalamic neurons following a stressful event. J. Mol. Endocrinol. 2005, 35(1):159-164. (Aug).
80. Kash T.L., Winder D.G. Neuropeptide Y and corticotropin-releasing factor bi-directionally modulate inhibitory synaptic transmission in the bed nucleus of the stria terminalis. Neuropharmacology 2006, 51(5):1013-1022. (Oct).
81. Kask A., Harro J., von Horsten S., Redrobe J.P., Dumont Y., Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci. Biobehav. Rev. 2002, 26(3):259-283. (May).
82. Kask A., Rago L., Harro J. Anxiolytic-like effect of neuropeptide Y (NPY) and NPY13-36 microinjected into vicinity of locus coeruleus in rats. Brain Res. 1998, 788(1-2):345-348. (Mar 30).
83. Kask A., Vasar E., Heidmets L.T., Allikmets L., Wikberg J.E. Neuropeptide Y Y(5) receptor antagonist CGP71683A: the effects on food intake and anxiety-related behavior in the rat. Eur. J. Pharmacol. 2001, 414(2-3):215-224. (Mar 2).
84. Kerkerian L., Bosler O., Pelletier G., Nieoullon A. Striatal neuropeptide Y neurones are under the influence of the nigrostriatal dopaminergic pathway: immunohistochemical evidence. Neurosci. Lett. 1986, 66(1):106-112. (May 6).
85. Kloster E., Saft C., Akkad D.A., Epplen J.T., Arning L. Association of age at onset in Huntington disease with functional promoter variations in NPY and NPY2R. J. Mol. Med. (Berl.) 2014, 92(2):177-184. (Feb).
86. Koide S., Onishi H., Hashimoto H., Kai T., Yamagami S. Plasma neuropeptide Y is reduced in patients with Alzheimer's disease. Neurosci. Lett. 1995, 198(2):149-151. (Sep 29).
87. Kolsch H., Lutjohann D., Jessen F., Urbach H., von Bergmann K., Maier W., et al. Polymorphism in neuropeptide Y influences CSF cholesterol levels but is no major risk factor of Alzheimer's disease. J. Neural Transm. 2006, 113(2):231-238. (Feb).
88. Kopp J., Xu Z.Q., Zhang X., Pedrazzini T., Herzog H., Kresse A., et al. Expression of the neuropeptide Y Y1 receptor in the CNS of rat and of wild-type and Y1 receptor knock-out mice. Focus on immunohistochemical localization. Neuroscience 2002, 111(3):443-532.
89. Krolow R., Noschang C., Arcego D.M., Huffell A.P., Marcolin M.L., Benitz A.N., et al. Sex-specific effects of isolation stress and consumption of palatable diet during the prepubertal period on metabolic parameters. Metabolism 2013, 62(9):1268-1278. (Sep).
90. Kuo L.E., Kitlinska J.B., Tilan J.U., Li L., Baker S.B., Johnson M.D., et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat. Med. 2007, 13(7):803-811. (Jul).
91. Lach G., de Lima T.C. Role of NPY Y1 receptor on acquisition, consolidation and extinction on contextual fear conditioning: dissociation between anxiety, locomotion and non-emotional memory behavior. Neurobiol. Learn. Mem. 2013, 103:26-33. (Jul).
92. Lacroix J.S., Ricchetti A.P., Morel D., Mossimann B., Waeber B., Grouzmann E. Intranasal administration of neuropeptide Y in man: systemic absorption and functional effects. Br. J. Pharmacol. 1996, 118(8):2079-2084. (Aug).
93. Laukova M., Alaluf L.G., Serova L.I., Arango V., Sabban E.L. Early intervention with intranasal NPY prevents single prolonged stress-triggered impairments in hypothalamus and ventral hippocampus in male rats. Endocrinology 2014, 155(10):3920-3933. (Oct).
94. Leitermann R.J., Sajdyk T.J., Urban J.H. Cell-specific expression of calcineurin immunoreactivity within the rat basolateral amygdala complex and colocalization with the neuropeptide Y Y1 receptor. J. Chem. Neuroanat. 2012, 45(1-2):50-56. (Oct).
95. Lin E.J., Lin S., Aljanova A., During M.J., Herzog H. Adult-onset hippocampal-specific neuropeptide Y overexpression confers mild anxiolytic effect in mice. Eur. Neuropsychopharmacol. 2010, 20(3):164-175. (Mar).
96. Lindell S.G., Schwandt M.L., Sun H., Sparenborg J.D., Bjork K., Kasckow J.W., et al. Functional NPY variation as a factor in stress resilience and alcohol consumption in rhesus macaques. Arch. Gen. Psychiatry 2010, 67(4):423-431. (Apr).
97. Longo A., Mele P., Bertocchi I., Oberto A., Bachmann A., Bartolomucci A., et al. Conditional inactivation of neuropeptide Y Y1 receptors unravels the role of Y1 and Y5 receptors coexpressing neurons in anxiety. Biol. Psychiatry 2014, 76(11):840-849. (Dec 1).
98. Longo A., Oberto A., Mele P., Mattiello L., Pisu M.G., Palanza P., et al. NPY-Y1 coexpressed with NPY-Y5 receptors modulate anxiety but not mild social stress response in mice. Genes Brain Behav. 2015, 14(7):534-542. (Sep).
99. Ma Y., Zhan M., OuYang L., Li Y., Chen S., Wu J., et al. The effects of unilateral 6-OHDA lesion in medial forebrain bundle on the motor, cognitive dysfunctions and vulnerability of different striatal interneuron types in rats. Behav. Brain Res. 2014, 266:37-45. (Jun 1).
100. Maniam J., Morris M.J. The link between stress and feeding behaviour. Neuropharmacology 2012, 63(1):97-110. (Jul).
101. Markaki E., Ellul J., Kefalopoulou Z., Trachani E., Theodoropoulou A., Kyriazopoulou V., et al. The role of ghrelin, neuropeptide Y and leptin peptides in weight gain after deep brain stimulation for Parkinson's disease. Stereotact. Funct. Neurosurg. 2012, 90(2):104-112.
102. Martignoni E., Blandini F., Petraglia F., Pacchetti C., Bono G., Nappi G. Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. J. Neural Transm. Park. Dis. Dement. Sect. 1992, 4(3):191-205.
103. Mazurek M.F., Garside S., Beal M.F. Cortical peptide changes in Huntington's disease may be independent of striatal degeneration. Ann. Neurol. 1997, 41(4):540-547. (Apr).
104. McDougall S.J., Widdop R.E., Lawrence A.J. Differential gene expression in WKY and SHR brain following acute and chronic air-puff stress. Brain Res. Mol. Brain Res. 2005, 133(2):329-336. (Feb 18).
105. McGonigle P. Peptide therapeutics for CNS indications. Biochem. Pharmacol. 2012, 83(5):559-566. (Mar 1).
106. McGuire J., Herman J.P., Horn P.S., Sallee F.R., Sah R. Enhanced fear recall and emotional arousal in rats recovering from chronic variable stress. Physiol. Behav. 2010, 101(4):474-482. (Nov 2).
107. McGuire J.L., Larke L.E., Sallee F.R., Herman J.P., Sah R. Differential regulation of neuropeptide Y in the amygdala and prefrontal cortex during recovery from chronic variable stress. Front. Behav. Neurosci. 2011, 5:54.
108. Melhorn S.J., Krause E.G., Scott K.A., Mooney M.R., Johnson J.D., Woods S.C., et al. Meal patterns and hypothalamic NPY expression during chronic social stress and recovery. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010, 299(3):R813-R822. (Sep).
109. Mickey B.J., Zhou Z., Heitzeg M.M., Heinz E., Hodgkinson C.A., Hsu D.T., et al. Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch. Gen. Psychiatry 2011, 68(2):158-166. (Feb).
110. Minthon L., Edvinsson L., Gustafson L. Correlation between clinical characteristics and cerebrospinal fluid neuropeptide Y levels in dementia of the Alzheimer type and frontotemporal dementia. Alzheimer Dis. Assoc. Disord. 1996, 10(4):197-203. (Winter).
111. Molosh A.I., Sajdyk T.J., Truitt W.A., Zhu W., Oxford G.S., Shekhar A. NPY Y1 receptors differentially modulate GABAA and NMDA receptors via divergent signal-transduction pathways to reduce excitability of amygdala neurons. Neuropsychopharmacology 2013, 38(7):1352-1364. (Jun).
112. Morales-Medina J.C., Dominguez-Lopez S., Gobbi G., Beck-Sickinger A.G., Quirion R. The selective neuropeptide Y Y5 agonist [cPP(1-7),NPY(19-23),Ala31,Aib32,Gln34]hPP differently modulates emotional processes and body weight in the rat. Behav. Brain Res. 2012, 233(2):298-304. (Aug 1).
113. Morales-Medina J.C., Dumont Y., Quirion R. A possible role of neuropeptide Y in depression and stress. Brain Res. 2010, 1314:194-205. (Feb 16).
114. Morgan C.A., Rasmusson A.M., Winters B., Hauger R.L., Morgan J., Hazlett G., et al. Trauma exposure rather than posttraumatic stress disorder is associated with reduced baseline plasma neuropeptide-levels. Biol. Psychiatry 2003, 54(10):1087-1091. (Nov 15).
115. Morin L.P. Neuroanatomy of the extended circadian rhythm system. Exp. Neurol. 2013, 243:4-20. (May).
116. Nakajima M., Inui A., Asakawa A., Momose K., Ueno N., Teranishi A., et al. Neuropeptide Y produces anxiety via Y2-type receptors. Peptides 1998, 19(2):359-363.
117. Nishi D., Hashimoto K., Noguchi H., Matsuoka Y. Serum neuropeptide Y in accident survivors with depression or posttraumatic stress disorder. Neurosci. Res. 2014, 83:8-12. (Jun).
118. Obuchowicz E., Antkiewicz-Michaluk L., Romanska I., Herman Z.S. Increased striatal neuropeptide Y immunoreactivity and its modulation by deprenyl, clonidine and l-DOPA in MPTP-treated mice. J. Neural Transm. 2003, 110(12):1375-1391. (Dec).
119. Olesen M.V., Christiansen S.H., Gotzsche C.R., Holst B., Kokaia M., Woldbye D.P. Y5 neuropeptide Y receptor overexpression in mice neither affects anxiety- and depression-like behaviours nor seizures but confers moderate hyperactivity. Neuropeptides 2012, 46(2):71-79. (Apr).
120. Olesen M.V., Christiansen S.H., Gotzsche C.R., Nikitidou L., Kokaia M., Woldbye D.P. Neuropeptide Y Y1 receptor hippocampal overexpression via viral vectors is associated with modest anxiolytic-like and proconvulsant effects in mice. J. Neurosci. Res. 2012, 90(2):498-507. (Feb).
121. Painsipp E., Herzog H., Holzer P. Implication of neuropeptide-Y2 receptors in the effects of immune stress on emotional, locomotor and social behavior of mice. Neuropharmacology 2008, 55(1):117-126. (Jul).
122. Painsipp E., Wultsch T., Edelsbrunner M.E., Tasan R.O., Singewald N., Herzog H., et al. Reduced anxiety-like and depression-related behavior in neuropeptide Y Y4 receptor knockout mice. Genes Brain Behav. 2008, 7(5):532-542. (Jul).
123. Parker R.M., Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur. J. Neurosci. 1999, 11(4):1431-1448. (Apr).
124. Paternain L., Batlle M.A., De la Garza A.L., Milagro F.I., Martinez J.A., Campion J. Transcriptomic and epigenetic changes in the hypothalamus are involved in an increased susceptibility to a high-fat-sucrose diet in prenatally stressed female rats. Neuroendocrinology 2012, 96(3):249-260.
125. Perez-Navarro E., Canals J.M., Gines S., Alberch J. Cellular and molecular mechanisms involved in the selective vulnerability of striatal projection neurons in Huntington's disease. Histol. Histopathol. 2006, 21(11):1217-1232. (Nov).
126. Primeaux S.D., Wilson S.P., Cusick M.C., York D.A., Wilson M.A. Effects of altered amygdalar neuropeptide Y expression on anxiety-related behaviors. Neuropsychopharmacology 2005, 30(9):1589-1597. (Sep).
127. Proto C., Romualdi D., Cento R.M., Spada R.S., Di Mento G., Ferri R., et al. Plasma levels of neuropeptides in Alzheimer's disease. Gynecol. Endocrinol. 2006, 22(4):213-218. (Apr).
128. Quarta D., Leslie C.P., Carletti R., Valerio E., Caberlotto L. Central administration of NPY or an NPY-Y5 selective agonist increase in vivo extracellular monoamine levels in mesocorticolimbic projecting areas. Neuropharmacology 2011, 60(2-3):328-335. (Feb-Mar).
129. Ramos B., Baglietto-Vargas D., del Rio J.C., Moreno-Gonzalez I., Santa-Maria C., Jimenez S., et al. Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease. Neurobiol. Aging 2006, 27(11):1658-1672. (Nov).
130. Rangani R.J., Upadhya M.A., Nakhate K.T., Kokare D.M., Subhedar N.K. Nicotine evoked improvement in learning and memory is mediated through NPY Y1 receptors in rat model of Alzheimer's disease. Peptides 2012, 33(2):317-328. (Feb).
131. Rasmusson A.M., Hauger R.L., Morgan C.A., Bremner J.D., Charney D.S., Southwick S.M. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol. Psychiatry 2000, 47(6):526-539. (Mar 15).
132. Reichmann F., Hassan A.M., Farzi A., Jain P., Schuligoi R., Holzer P. Dextran sulfate sodium-induced colitis alters stress-associated behaviour and neuropeptide gene expression in the amygdala-hippocampus network of mice. Sci. Rep. 2015, 5:9970. (Jun 12).
133. Ricci S., Fuso A., Ippoliti F., Businaro R. Stress-induced cytokines and neuronal dysfunction in Alzheimer's disease. J. Alzheimers Dis. 2012, 28(1):11-24.
134. Rose J.B., Crews L., Rockenstein E., Adame A., Mante M., Hersh L.B., et al. Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease. J. Neurosci. 2009, 29(4):1115-1125. (Jan 28).
135. Roseboom P.H., Nanda S.A., Fox A.S., Oler J.A., Shackman A.J., Shelton S.E., et al. Neuropeptide Y receptor gene expression in the primate amygdala predicts anxious temperament and brain metabolism. Biol. Psychiatry 2014, 76(11):850-857. (Dec 1).
136. Rybkin I.I., Zhou Y., Volaufova J., Smagin G.N., Ryan D.H., Harris R.B. Effect of restraint stress on food intake and body weight is determined by time of day. Am. J. Physiol. 1997, 273(Pt 2):R1612-R1622. (Nov).
137. Sabban E.L., Serova L.I., Alaluf L.G., Laukova M., Peddu C. Comparative effects of intranasal neuropeptide Y and HS014 in preventing anxiety and depressive-like behavior elicited by single prolonged stress. Behav. Brain Res. 2014, 24. (Dec).
138. Sah R., Ekhator N.N., Jefferson-Wilson L., Horn P.S., Geracioti T.D. Cerebrospinal fluid neuropeptide Y in combat veterans with and without posttraumatic stress disorder. Psychoneuroendocrinology 2014, 40:277-283. (Feb).
139. Sah R., Ekhator N.N., Strawn J.R., Sallee F.R., Baker D.G., Horn P.S., et al. Low cerebrospinal fluid neuropeptide Y concentrations in posttraumatic stress disorder. Biol. Psychiatry 2009, 66(7):705-707. (Oct 1).
140. Sajdyk T.J., Johnson P.L., Leitermann R.J., Fitz S.D., Dietrich A., Morin M., et al. Neuropeptide Y in the amygdala induces long-term resilience to stress-induced reductions in social responses but not hypothalamic-adrenal-pituitary axis activity or hyperthermia. J. Neurosci. 2008, 28(4):893-903. (Jan 23).
141. Sajdyk T.J., Schober D.A., Smiley D.L., Gehlert D.R. Neuropeptide Y-Y2 receptors mediate anxiety in the amygdala. Pharmacol. Biochem. Behav. 2002, 71(3):419-423. (Mar).
142. Sajdyk T.J., Shekhar A., Gehlert D.R. Interactions between NPY and CRF in the amygdala to regulate emotionality. Neuropeptides 2004, 38(4):225-234. (Aug).
143. Sajdyk T.J., Vandergriff M.G., Gehlert D.R. Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur. J. Pharmacol. 1999, 368(2-3):143-147. (Mar 5).
144. Sandvik A.M., Bartone P.T., Hystad S.W., Phillips T.M., Thayer J.F., Johnsen B.H. Psychological hardiness predicts neuroimmunological responses to stress. Psychol. Health Med. 2013, 18(6):705-713.
145. Selye H. A syndrome produced by diverse nocuous agents. 1936. J. Neuropsychiatr. Clin. Neurosci. 1998, 10(2):230-231. (Spring).
146. Serova L.I., Laukova M., Alaluf L.G., Pucillo L., Sabban E.L. Intranasal neuropeptide Y reverses anxiety and depressive-like behavior impaired by single prolonged stress PTSD model. Eur. Neuropsychopharmacol. 2014, 24(1):142-147. (Jan).
147. Serova L.I., Tillinger A., Alaluf L.G., Laukova M., Keegan K., Sabban E.L. Single intranasal neuropeptide Y infusion attenuates development of PTSD-like symptoms to traumatic stress in rats. Neuroscience 2013, 236:298-312. (Apr 16).
148. Shoblock J.R., Welty N., Nepomuceno D., Lord B., Aluisio L., Fraser I., et al. In vitro and in vivo characterization of JNJ-31020028 (N-(4-[4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl-3]-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y(2) receptor. Psychopharmacology 2010, 208(2):265-277. (Feb).
149. Silva A.P., Xapelli S., Grouzmann E., Cavadas C. The putative neuroprotective role of neuropeptide Y in the central nervous system. Curr. Drug Targets CNS Neurol. Disord. 2005, 4(4):331-347. (Aug).
150. Smialowska M., Wieronska J.M., Domin H., Zieba B. The effect of intrahippocampal injection of group II and III metobotropic glutamate receptor agonists on anxiety; the role of neuropeptide Y. Neuropsychopharmacology 2007, 32(6):1242-1250. (Jun).
151. Sommer W.H., Lidstrom J., Sun H., Passer D., Eskay R., Parker S.C., et al. Human NPY promoter variation rs16147:T>C as a moderator of prefrontal NPY gene expression and negative affect. Hum. Mutat. 2010, 31(8):E1594-E1608. (Aug).
152. Sorensen G., Lindberg C., Wortwein G., Bolwig T.G., Woldbye D.P. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. J. Neurosci. Res. 2004, 77(5):723-729. (Sep 1).
153. Sundstrom G., Larsson T.A., Xu B., Heldin J., Larhammar D. Interactions of zebrafish peptide YYb with the neuropeptide Y-family receptors Y4, Y7, Y8a, and Y8b. Front. Neurosci. 2013, 7:29. (Mar 15).
154. Suo L., Zhao L., Si J., Liu J., Zhu W., Chai B., et al. Predictable chronic mild stress in adolescence increases resilience in adulthood. Neuropsychopharmacology 2013, 38(8):1387-1400. (Jul).
155. Sweerts B.W., Jarrott B., Lawrence A.J. The effect of acute and chronic restraint on the central expression of prepro-neuropeptide Y mRNA in normotensive and hypertensive rats. J. Neuroendocrinol. 2001, 13(7):608-617. (Jul).
156. Sweis B.M., Veverka K.K., Dhillon E.S., Urban J.H., Lucas L.R. Individual differences in the effects of chronic stress on memory: behavioral and neurochemical correlates of resiliency. Neuroscience 2013, 246:142-159. (Aug 29).
157. Tasan R.O., Lin S., Hetzenauer A., Singewald N., Herzog H., Sperk G. Increased novelty-induced motor activity and reduced depression-like behavior in neuropeptide Y (NPY)-Y4 receptor knockout mice. Neuroscience 2009, 158(4):1717-1730. (Feb 18).
158. Tasan R.O., Nguyen N.K., Weger S., Sartori S.B., Singewald N., Heilbronn R., et al. The central and basolateral amygdala are critical sites of neuropeptide Y/Y2 receptor-mediated regulation of anxiety and depression. J. Neurosci. 2010, 30(18):6282-6290. (May 5).
159. Tatemoto K., Carlquist M., Mutt V. Neuropeptide Y-novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982, 296(5858):659-660. (Apr 15).
160. Thorsell A., Carlsson K., Ekman R., Heilig M. Behavioral and endocrine adaptation, and up-regulation of NPY expression in rat amygdala following repeated restraint stress. Neuroreport 1999, 10(14):3003-3007. (Sep 29).
161. Thorsell A., Michalkiewicz M., Dumont Y., Quirion R., Caberlotto L., Rimondini R., et al. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(23):12852-12857. (Nov 7).
162. Thorsell A., Svensson P., Wiklund L., Sommer W., Ekman R., Heilig M. Suppressed neuropeptide Y (NPY) mRNA in rat amygdala following restraint stress. Regul. Pept. 1998, 75-76:247-254. (Sep 25).
163. Trent N.L., Menard J.L. Lateral septal infusions of the neuropeptide Y Y2 receptor agonist, NPY(13-36) differentially affect different defensive behaviors in male, Long Evans rats. Physiol. Behav. 2013, 110-111:20-29. (Feb 17).
164. Tschenett A., Singewald N., Carli M., Balducci C., Salchner P., Vezzani A., et al. Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur. J. Neurosci. 2003, 18(1):143-148. (Jul).
165. Upton K.R., Riley L.G. Acute stress inhibits food intake and alters ghrelin signaling in the brain of tilapia (Oreochromis mossambicus). Domest. Anim. Endocrinol. 2013, 44(3):157-164. (Apr).
166. Verma D., Wood J., Lach G., Herzog H., Sperk G., Tasan R. Hunger promotes fear extinction by activation of an amygdala microcircuit. Neuropsychopharmacology 2015, (Jun 11).
167. Walker M.W., Wolinsky T.D., Jubian V., Chandrasena G., Zhong H., Huang X., et al. The novel neuropeptide Y Y5 receptor antagonist Lu AA33810 [N-[[trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl]me thyl]-methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of stress sensitivity. J. Pharmacol. Exp. Ther. 2009, 328(3):900-911. (Mar).
168. Wang S.X., Chen J.X., Yue G.X., Bai M.H., Kou M.J., Jin Z.Y. Xiaoyaosan decoction regulates changes in neuropeptide y and leptin receptor in the rat arcuate nucleus after chronic immobilization stress. Evid. Based Complement. Alternat. Med. 2012, 2012.
169. Whitcomb D.C., Taylor I.L., Vigna S.R. Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain. Am. J. Physiol. 1990, 259(Pt 1):G687-G691. (Oct).
170. White J.D. Neuropeptide Y: a central regulator of energy homeostasis. Regul. Pept. 1993, 49(2):93-107. (Dec 10).
171. Wilcock D.M., Lewis M.R., Van Nostrand W.E., Davis J., Previti M.L., Gharkholonarehe N., et al. Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J. Neurosci. 2008, 28(7):1537-1545. (Feb 13).
172. Witt S.H., Buchmann A.F., Blomeyer D., Nieratschker V., Treutlein J., Esser G., et al. An interaction between a neuropeptide Y gene polymorphism and early adversity modulates endocrine stress responses. Psychoneuroendocrinology 2011, 36(7):1010-1020. (Aug).
173. Wolak M.L., DeJoseph M.R., Cator A.D., Mokashi A.S., Brownfield M.S., Urban J.H. Comparative distribution of neuropeptide Y Y1 and Y5 receptors in the rat brain by using immunohistochemistry. J. Comp. Neurol. 2003, 464(3):285-311. (Sep 22).
174. Yan H., Yang J., Marasco J., Yamaguchi K., Brenner S., Collins F., et al. Cloning and functional expression of cDNAs encoding human and rat pancreatic polypeptide receptors. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(10):4661-4665. (May 14).
175. Yehuda R., Brand S., Yang R.K. Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. Biol. Psychiatry 2006, 59(7):660-663. (Apr 1).
176. Zaben M.J., Gray W.P. Neuropeptides and hippocampal neurogenesis. Neuropeptides 2013, 47(6):431-438. (Dec).
177. Zakrzewska K.E., Cusin I., Stricker-Krongrad A., Boss O., Ricquier D., Jeanrenaud B., et al. Induction of obesity and hyperleptinemia by central glucocorticoid infusion in the rat. Diabetes 1999, 48(2):365-370. (Feb).
178. Zambello E., Zanetti L., Hedou G.F., Angelici O., Arban R., Tasan R.O., et al. Neuropeptide Y-Y2 receptor knockout mice: influence of genetic background on anxiety-related behaviors. Neuroscience 2011, 176:420-430. (Mar 10).
179. Zhang L., Bijker M.S., Herzog H. The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacol. Ther. 2011, 131(1):91-113. (Jul).
180. Zhou Z., Zhu G., Hariri A.R., Enoch M.A., Scott D., Sinha R., et al. Genetic variation in human NPY expression affects stress response and emotion. Nature 2008, 452(7190):997-1001. (Apr 24).